Interpretation of the Chinese guidelines for diagnosis and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (2025 edition)
10.3760/cma.j.cn113694-20250430-00255
- VernacularTitle:中国髓鞘少突胶质细胞糖蛋白抗体相关疾病诊断与治疗指南（2025版）解读
- Author:
Honghao WANG
1
;
Xueqiang HU
Author Information
1. 广州市第一人民医院神经内科，广州510180
- Publication Type:Journal Article
- Keywords:
Myelin-oligodendrocyte glycoprotein;
Diagnosis;
Treatment;
Guideline
- From:
Chinese Journal of Neurology
2025;58(7):669-672
- CountryChina
- Language:Chinese
-
Abstract:
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified inflammatory demyelinating disease of the central nervous system, with strong heterogeneity in clinical manifestations and many challenges in diagnosis and treatment. At present, some international MOGAD diagnosis and treatment guidelines and consensus are mostly based on western population data, so Chinese neuroimmunology experts have been committed to customizing MOGAD diagnosis and treatment guidelines suitable for Chinese population. The Chinese guidelines for diagnosis and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (2025 edition) has comprehensively revised the disease definition, diagnostic criteria, imaging features, treatment strategies, etc., based on the latest evidence-based research at home and abroad, as well as multi-center clinical research data in China. Some important revisions in the new guideline were interpreted in this article.
